NasdaqCM - Nasdaq Real Time Price USD

Tempest Therapeutics, Inc. (TPST)

Compare
0.7116 -0.0084 (-1.17%)
At close: December 20 at 4:00:01 PM EST
0.7300 +0.02 (+2.59%)
After hours: December 20 at 7:58:13 PM EST
Currency in USD All numbers in thousands
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Expense
35,622.0000
29,157.0000
34,640.0000
26,986.0000
19,298.0000
Operating Income
-35,622.0000
-29,157.0000
-34,640.0000
-26,986.0000
-19,298.0000
Net Non Operating Interest Income Expense
89.0000
-349.0000
-1,018.0000
-1,275.0000
90.0000
Other Income Expense
--
15.0000
-51.0000
-41.0000
--
Pretax Income
-35,518.0000
-29,491.0000
-35,709.0000
-28,302.0000
-19,208.0000
Net Income Common Stockholders
-35,518.0000
-29,491.0000
-35,709.0000
-28,302.0000
-19,208.0000
Diluted NI Available to Com Stockholders
-35,518.0000
-29,491.0000
-35,709.0000
-28,302.0000
-19,208.0000
Basic EPS
-1.53
-1.91
-3.09
-7.47
-2.89
Diluted EPS
-1.53
-1.91
-3.09
-7.47
-2.89
Basic Average Shares
22,525.0370
15,416.2030
11,556.3110
3,790.3030
6,635.3030
Diluted Average Shares
22,525.0370
15,416.2030
11,556.3110
3,790.3030
6,635.3030
Total Operating Income as Reported
-35,622.0000
-29,157.0000
-34,640.0000
-26,986.0000
-19,298.0000
Total Expenses
35,622.0000
29,157.0000
34,640.0000
26,986.0000
19,298.0000
Net Income from Continuing & Discontinued Operation
-35,518.0000
-29,491.0000
-35,709.0000
-28,302.0000
-19,208.0000
Normalized Income
-35,518.0000
-29,491.0000
-35,709.0000
-28,302.0000
-19,208.0000
Interest Income
1,535.0000
1,100.0000
600.0000
7.0000
90.0000
Interest Expense
1,446.0000
1,449.0000
1,618.0000
1,282.0000
--
Net Interest Income
89.0000
-349.0000
-1,018.0000
-1,275.0000
90.0000
EBIT
-34,072.0000
-28,042.0000
-34,091.0000
-27,020.0000
-19,208.0000
EBITDA
-33,647.0000
-27,661.0000
-33,453.0000
-26,646.0000
-18,869.0000
Reconciled Depreciation
425.0000
381.0000
638.0000
374.0000
339.0000
Net Income from Continuing Operation Net Minority Interest
-35,518.0000
-29,491.0000
-35,709.0000
-28,302.0000
-19,208.0000
Normalized EBITDA
-33,647.0000
-27,661.0000
-33,453.0000
-26,646.0000
-18,869.0000
12/31/2020 - 11/12/2012

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers